Report

Global Critical Limb Ischemia Treatment Market Size study, by Treatment Type (Devices [Embolic Protection Devices, Peripheral Dilatation Systems], Medications [Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents], Surgery), and Regional Forecasts 2021-2027

  • Publish Date: Mar,2022
  • Report ID: QI037
  • Page : 250
  • Report Type : PDF (Email)
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Critical Limb Ischemia Treatment Market, by Region, 2019-2027 (USD Billion)
1.2.2. Critical Limb Ischemia Treatment Market, by Treatment Type, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Critical Limb Ischemia Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Critical Limb Ischemia Treatment Market Dynamics
3.1. Critical Limb Ischemia Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rising geriatric population globally
3.1.1.2. Prevalence of diabetic and obese population
3.1.2. Market Challenges
3.1.2.1. Costly treatment paired with low awareness
3.1.3. Market Opportunities
3.1.3.1. Increasing investments into research & development
Chapter 4. Global Critical Limb Ischemia Treatment Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Critical Limb Ischemia Treatment Market, by Treatment Type
5.1. Market Snapshot
5.2. Global Critical Limb Ischemia Treatment Market by Treatment Type, Performance - Potential Analysis
5.3. Global Critical Limb Ischemia Treatment Market Estimates & Forecasts by Treatment Type 2018-2027 (USD Billion)
5.4. Critical Limb Ischemia Treatment Market, Sub Segment Analysis
5.4.1. Devices
5.4.1.1. Embolic Protection Devices
5.4.1.2. Peripheral Dilatation Systems
5.4.2. Medications
5.4.2.1. Antiplatelet Drugs
5.4.2.2. Antihypertensive agents
5.4.2.3. Lipid-lowering agents
5.4.2.4. Others

Chapter 6. Global Critical Limb Ischemia Treatment Market, Regional Analysis
6.1. Critical Limb Ischemia Treatment Market, Regional Market Snapshot
6.2. North America Critical Limb Ischemia Treatment Market
6.2.1. U.S. Critical Limb Ischemia Treatment Market
6.2.1.1. Treatment Type breakdown estimates & forecasts, 2018-2027
6.2.2. Canada Critical Limb Ischemia Treatment Market
6.3. Europe Critical Limb Ischemia Treatment Market Snapshot
6.3.1. U.K. Critical Limb Ischemia Treatment Market
6.3.2. Germany Critical Limb Ischemia Treatment Market
6.3.3. France Critical Limb Ischemia Treatment Market
6.3.4. Spain Critical Limb Ischemia Treatment Market
6.3.5. Italy Critical Limb Ischemia Treatment Market
6.3.6. Rest of Europe Critical Limb Ischemia Treatment Market
6.4. Asia-Pacific Critical Limb Ischemia Treatment Market Snapshot
6.4.1. China Critical Limb Ischemia Treatment Market
6.4.2. India Critical Limb Ischemia Treatment Market
6.4.3. Japan Critical Limb Ischemia Treatment Market
6.4.4. Australia Critical Limb Ischemia Treatment Market
6.4.5. South Korea Critical Limb Ischemia Treatment Market
6.4.6. Rest of Asia Pacific Critical Limb Ischemia Treatment Market
6.5. Latin America Critical Limb Ischemia Treatment Market Snapshot
6.5.1. Brazil Critical Limb Ischemia Treatment Market
6.5.2. Mexico Critical Limb Ischemia Treatment Market
6.6. Rest of The World Critical Limb Ischemia Treatment Market

Chapter 7. Competitive Intelligence
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Medtronic
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Product Summary
7.2.1.5. Recent Developments
7.2.2. LimFlow SA
7.2.3. Cynata Therapeutics Ltd.
7.2.4. Cardiovascular Systems Inc.
7.2.5. Eli Lilly and Company
7.2.6. Abbott Laboratories
7.2.7. Rexgenero Ltd.
7.2.8. ThermoGenesis Holdings Inc.
7.2.9. Teva Pharmaceuticals
7.2.10. Cesca Therapeutics
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption